Pharma & Healthcare in Argentina: Turning a Corner?
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Bioceres is an Argentina-based firm that manages investments in agricultural biotechnology and related sciences. It was founded in December 2001 by 23 farmers and is now owned by more than 270 shareholders, most of them innovative farmers but also coops and different actors from the agro-industrial sector. Every year, Bioceres shareholders plant about 2.5 million hectares in different regions of Latin America.
Since its beginnings, Bioceres has been a bridge between the scientific community and the agricultural production sector, fostering public-private associations and the development of collaborative networks.
Bioceres is a firm open to new shareholders with a shared dream-developing new technologies that help us use natural resources in a more efficient way while increasing and stabilizing the productivity of ecosystems.
Bioceres goes from genes to seeds, linking the laboratory to the field, adding value in every stage, and building and strengthening public-private partnerships.
CONTACT DETAILS
Ocampo 210 bis, predio CCT Rosario, (2000) Rosario, Santa Fe, Argentina
Phone: (54) 341 486 1100 Fax:(54) 341 486 1100
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical…
Gala Díaz Langou, a senior analyst and executive director at Argentina’s premier think tank CIPPEC, assesses the country’s recent transformative journey under President Milei. Drawing on 25 years of institutional…
Keila Barral, founder of Cromodata, brings together a personal journey of resilience and a career in technology to address one of Latin America’s biggest healthcare challenges: fragmented patient data. After…
Argentina’s pharmaceutical industry combines a robust domestic manufacturing base with growing international reach and regulatory credibility. In this interview, Mauricio Claverí, Chief Economist at CILFA, explores how local companies are…
Juan Jose Marconi, Executive Director of Cooperala, offers a unique perspective shaped by decades of leadership across Argentina’s pharmaceutical and healthcare sectors. With a strong academic background in applied mathematics,…
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
See our Cookie Privacy Policy Here
